{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:22:02Z","timestamp":1791908522608,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00 MD015767"],"award-info":[{"award-number":["R00 MD015767"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaci.2024.10.028","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T12:03:07Z","timestamp":1730980987000},"page":"1584-1594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy"],"prefix":"10.1016","volume":"155","author":[{"given":"Javier S.","family":"Cabrera-Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreofe O.","family":"Odejide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Kupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv S.","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-1470","authenticated-orcid":false,"given":"Ayobami","family":"Akenroye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.10.028_bib1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: first global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2024.10.028_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.10.028_bib3","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.028_bib4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.028_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2022.11.021","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"151","author":"Nopsopon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.028_bib6","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation","volume":"151","author":"Akenroye","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.028_bib7","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.028_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2024.10.028_bib9","first-page":"CD013206","article-title":"Systemic treatments for eczema: a network meta-analysis","volume":"9","author":"Sawangjit","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2024.10.028_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","article-title":"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"91","author":"Hasan","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2024.10.028_bib11","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.12788\/cutis.0074","article-title":"Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma","volume":"106","author":"Hollins","year":"2020","journal-title":"Cutis"},{"key":"10.1016\/j.jaci.2024.10.028_bib12","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/ijd.16388","article-title":"Cutaneous T-cell lymphoma following dupilumab use: a systematic review","volume":"62","author":"Park","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2024.10.028_bib13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.12788\/cutis.0066","article-title":"Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab","volume":"106","author":"Mollanazar","year":"2020","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.jaci.2024.10.028_bib14","article-title":"Role of IL-4 and IL-13 in cutaneous T cell lymphoma","volume":"14","author":"Mazzetto","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jaci.2024.10.028_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5114\/ada.2016.63881","article-title":"The role of polymorphism of interleukin-2, -10, -13 and TNF-alpha genes in cutaneous T-cell lymphoma pathogenesis","volume":"33","author":"Nedoszytko","year":"2016","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jaci.2024.10.028_bib16","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/pds.4672","article-title":"Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA","volume":"27","author":"Fukazawa","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaci.2024.10.028_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41420-020-00321-y","article-title":"Benchmarking evolutionary tinkering underlying human-viral molecular mimicry shows multiple host pulmonary\u2013arterial peptides mimicked by SARS-CoV-2","volume":"6","author":"Venkatakrishnan","year":"2020","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jaci.2024.10.028_bib18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58040","article-title":"Knowledge synthesis of 100 million biomedical documents augments the deep expression profiling of coronavirus receptors","volume":"9","author":"Venkatakrishnan","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.jaci.2024.10.028_bib19","article-title":"Combining a pharmacological network model with a bayesian signal detection algorithm to improve the detection of adverse drug events","author":"Ji","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaci.2024.10.028_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12859-018-2137-y","article-title":"A simple method for exploring adverse drug events in patients with different primary diseases using spontaneous reporting system","volume":"19","author":"Noguchi","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jaci.2024.10.028_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","article-title":"Decision support methods for the detection of adverse events in post-marketing data","volume":"14","author":"Hauben","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jaci.2024.10.028_bib22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","article-title":"A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database","volume":"23","author":"Lindquist","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaci.2024.10.028_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2024.10.028_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaci.2024.10.028_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil\u2014free eyeballs on AERS pharmacovigilance data","volume":"30","author":"Bohm","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"D1","key":"10.1016\/j.jaci.2024.10.028_bib26","doi-asserted-by":"crossref","first-page":"D596","DOI":"10.1093\/nar\/gkab1020","article-title":"DISCO: a database of deeply integrated human single-cell omics data","volume":"50","author":"Li","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.jaci.2024.10.028_bib27","doi-asserted-by":"crossref","first-page":"D41","DOI":"10.1093\/nar\/gkx1094","article-title":"GenBank","volume":"46","author":"Benson","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaci.2024.10.028_bib28","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1158\/1078-0432.CCR-19-0148","article-title":"Single-cell lymphocyte heterogeneity in advanced cutaneous T-cell lymphoma skin tumors","volume":"25","author":"Gaydosik","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"55","key":"10.1016\/j.jaci.2024.10.028_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe2749","article-title":"Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4R\u03b1 blockade","volume":"6","author":"Bangert","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2024.10.028_bib30","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1038\/s41467-022-35319-w","article-title":"Spatial transcriptomics landscape of lesions from non-communicable inflammatory skin diseases","volume":"13","author":"Schabitz","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2024.10.028_bib31","article-title":"Cutaneous T cell lymphoma atlas reveals malignant Th2 cells supported by a B cell\u2013rich microenvironment","author":"Li","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.jaci.2024.10.028_bib32","article-title":"Dupilumab-associated eosinophilic granulomatosis with polyangiitis","volume":"14","author":"Persaud","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jaci.2024.10.028_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12890-023-02415-6","article-title":"Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report","volume":"23","author":"Suzaki","year":"2023","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaci.2024.10.028_bib34","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.10.028_bib35","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/jid.2013.503","article-title":"In\u00a0vitro assessment of IL-4\u2013 or IL-13\u2013mediated changes in the structural components of keratinocytes in mice and humans","volume":"134","author":"Omori-Miyake","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2024.10.028_bib36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/nmeth.4463","article-title":"SCENIC: single-cell regulatory network inference and clustering","volume":"14","author":"Aibar","year":"2017","journal-title":"Nat Methods"},{"key":"10.1016\/j.jaci.2024.10.028_bib37","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41587-021-01139-4","article-title":"Cell2location maps fine-grained cell types in spatial transcriptomics","volume":"40","author":"Kleshchevnikov","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2024.10.028_bib38","article-title":"Incidence of adverse events prompting switching between biologics among adults with asthma: a retrospective cohort study","author":"Akenroye","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.10.028_bib39","series-title":"Regeneron reports fourth quarter and full year 2023 financial and operating results","year":"2024"},{"key":"10.1016\/j.jaci.2024.10.028_bib42","first-page":"1","article-title":"Rapid progression of cutaneous T-cell lymphoma in a patient with erythroderma during dupilumab treatment, following prior sequential azathioprine, baricitinib and cyclosporine treatments","volume":"1","author":"Hsieh","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaci.2024.10.028_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdcr.2020.12.010","article-title":"Acceleration of cutaneous T-cell lymphoma following dupilumab administration","volume":"8","author":"Russomanno","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2024.10.028_bib44","article-title":"Cutaneous T-cell lymphoma progression: a potential dupilumab pitfall","volume":"15","author":"Malick","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jaci.2024.10.028_bib45","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jamadermatol.2023.3849","article-title":"Dupilumab-associated lymphoid reactions in patients with atopic dermatitis","volume":"159","author":"Boesjes","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2024.10.028_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0141076814562718","article-title":"The environment and disease: association or causation? 1965","volume":"108","author":"Hill","year":"2015","journal-title":"J R Soc Med"},{"key":"10.1016\/j.jaci.2024.10.028_bib47","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/1078-0432.CCR-07-0610","article-title":"Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"14","author":"Chong","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2024.10.028_bib48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.2022016690","article-title":"Malignant T cells induce skin barrier defects through cytokine-mediated JAK\/STAT signaling in cutaneous T-cell lymphoma","volume":"141","author":"Gluud","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.10.028_bib49","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood.V99.3.973","article-title":"Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3","volume":"99","author":"Nielsen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.10.028_bib50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/cyto.2000.0814","article-title":"Localization of human interleukin 13 receptor in non-haematopoietic cells","volume":"13","author":"Akaiwa","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2024.10.028_bib51","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.jid.2020.12.026","article-title":"SMOC1 and IL-4 and IL-13 cytokines interfere with Ca2+ mobilization in primary human keratinocytes","volume":"141","author":"Lyubchenko","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2024.10.028_bib52","doi-asserted-by":"crossref","first-page":"101520","DOI":"10.1016\/j.smim.2021.101520","article-title":"Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis","volume":"58","author":"Bridgewood","year":"2021","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaci.2024.10.028_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2022.03.013","article-title":"Th2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent Th17 type diseases including seronegative arthritis, enthesitis\/enthesopathy, but not humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2024.10.028_bib54","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41590-021-01067-0","article-title":"Homeostatic IL-13 in healthy skin directs dendritic cell differentiation to promote TH2 and inhibit TH17 cell polarization","volume":"22","author":"Mayer","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2024.10.028_bib55","article-title":"Sociodemographic characteristics of adverse event reporting","year":"2024","journal-title":"Spotlight on CDER science"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924011722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924011722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:28:55Z","timestamp":1777264135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924011722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0091674924011722"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.10.028","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}